The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Everolimus as second-line treatment in metastatic renal cell carcinoma (mRCC) after first-line pazopanib (The RESCUE study): A retrospective analysis by the Hellenic GU Cancer Group (HGUCG) with international collaboration.
 
Konstantinos Koutsoukos
No Relationships to Disclose
 
Marta Espinosa Montano
No Relationships to Disclose
 
Loukas Kontovinis
No Relationships to Disclose
 
Kimon Tzannis
No Relationships to Disclose
 
Angelos Koutras
No Relationships to Disclose
 
Christos Christodoulou
No Relationships to Disclose
 
Vasiliki Bozionelou
No Relationships to Disclose
 
Dimitra Stefanou
No Relationships to Disclose
 
Marios Bakogeorgos
No Relationships to Disclose
 
Nikolaos K. Kentepozidis
No Relationships to Disclose
 
Alexandros Ardavanis
No Relationships to Disclose
 
Haralabos Kalofonos
No Relationships to Disclose
 
Ignacio Duran
No Relationships to Disclose
 
Aristotelis Bamias
Honoraria - GlaxoSmithKline; Novartis
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Novartis
 
Konstantinos Papazisis
Honoraria - Amgen; GlaxoSmithKline; Novartis; Roche/Genentech
Consulting or Advisory Role - GlaxoSmithKline; Novartis
Speakers' Bureau - Novartis